In a crossover trial of 65 adults with IgA nephropathy, proteinuria responses to ambrisentan, henagliflozin and the combination were not correlated. UPCR fell 44% with combination vs 48% ambrisentan and 21% henagliflozin; combination had less fluid retention than ambrisentan.
RCTn = 65
Chen et al. Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial